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The Soluble Form of IL-1 Receptor Accessory
Protein Enhances the Ability of Soluble
Type II IL-1 Receptor to Inhibit IL-1 Action
brane protein, but the extracellular, ligand binding do-
main can be shed from the cell surface via proteolytic
cleavage, and remains able to bind IL-1 (Giri et al.,
1994). Natural circulating levels of soluble type II IL-1R
are approximately 1–5 ng/ml (Giri et al., 1994; Jouvenne
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Baltimore, Maryland 21201 Following binding of IL-1 or IL-1 to the type I IL-
1R, a second protein, the IL-1 receptor accessory pro-
tein (AcP), is recruited to the complex (Greenfeder et
Summary al., 1995). Both proteins, IL-1R and AcP, are required
for signaling. AcP can also be recruited to the transmem-
Regulation of the activity of the proinflammatory cyto- brane form of the type II IL-1R, once the latter has bound
kine IL-1 is complex, involving transcriptional and IL-1 (Lang et al., 1998; Malinowsky et al., 1998). Thus,
translational control, precursor processing, a receptor the type II IL-1R decoys not only IL-1, but also AcP,
antagonist (IL-1ra), and a decoy receptor. Here we away from productive association with the type I IL-1R,
report that the soluble form of the IL-1 receptor acces- enhancing its effectiveness as a negative regulator.
sory protein (AcP) increases the affinity of binding of In addition to the transmembrane form of AcP, another
human IL-1 and IL-1 to the soluble human type II form exists, encoded by an alternatively spliced mRNA
IL-1 receptor by approximately 100-fold, while leaving (Greenfeder et al., 1995; Jensen et al., 2000). This form
unaltered the low binding affinity of IL-1ra. Soluble contains only the extracellular domain of AcP and is
AcP is present in normal human serum at an average assumed to be secreted from cells and soluble in blood
concentration greater than 300 ng/ml. These findings
and extracellular fluids. It has been suggested that solu-
suggest that the soluble form of IL-1R AcP contributes
ble AcP might be recruited to the IL-1/IL-1R complex,
to the antagonism of IL-1 action by the type II decoy
which would prevent association of the full-length, sig-
receptor, adding another layer of complexity to the
nal-competent form of AcP. Soluble AcP would therebyregulation of IL-1 action.
function as yet another negative regulator of IL-1 activ-
ity. This action of soluble AcP has been difficult to dem-Introduction
onstrate, however (Jensen et al., 2000).
In the course of investigating the IL-1 inhibitory abilityThe proinflammatory cytokine interleukin-1 (IL-1) is
of soluble human type II IL-1 receptor in vivo, we unex-thought to play a role in many diseases, including arthri-
pectedly found that soluble human AcP can associatetis, heart disease, pancreatitis, multiple myeloma, and
with ligand-bound soluble IL1R-II. Association of sIL1R-stroke (see Dinarello, 1998, for review). Inhibition of IL-1
II with AcP increases the affinity of binding to both hu-is beneficial in many murine models of disease. Two
man IL-1and human IL-1by approximately two ordersnatural regulators of IL-1 activity exist that potentially
of magnitude, which now renders human sIL1R-II ancan be used for this purpose in human therapy. One of
effective inhibitor of the former as well as the latter. Inthese, IL-1 receptor antagonist or IL-1ra (Hannum et al.,
monkeys, efficient binding of IL-1 by soluble type II IL-1990; Eisenberg et al., 1990), binds to the signaling IL-1
1R absolutely requires soluble AcP. Circulating levelsreceptor (type I IL-1R) with high affinity but fails to elicit
of soluble AcP are remarkably high, averaging over 300a biological response. By blocking the receptor, how-
ng/ml in humans and even higher in monkeys and mice.ever, it interferes with the activity of the agonist IL-1
The mRNA encoding soluble AcP is expressed in almostforms IL-1 and IL-1. Treatment of rheumatoid arthritis
all tissues.patients with recombinant IL-1ra is of demonstrated
clinical benefit (Dayer et al., 2001). The other natural
regulator of IL-1 action is the type II IL-1 receptor
Results(McMahan et al., 1991; Colotta et al., 1993). Although
this protein binds tightly to IL-1, it lacks a cytoplasmic
Effect of sIL1R In Vivo in Rhesus Monkeysdomain and cannot signal; it therefore functions as a
Recombinant human soluble type II IL-1 receptor (shu-decoy receptor. The type II IL-1R also binds IL-1, but
with significantly lower affinity. It also binds poorly to IL1R-II) was administered to rhesus monkeys, and either
IL-1ra, with the result that the two regulators of IL-1 30 min or 2 hr later, the monkeys were injected with
activity complement rather than neutralize each other. LPS from E. coli. Two hemodynamic parameters, mean
The type II IL-1R is initially synthesized as a transmem- arterial pressure and systemic vascular resistance, suf-
fered precipitous drops over the course of 1–2 hr in
animals injected with LPS in the presence of the control*Correspondence: sims@amgen.com
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Figure 2. shuIL1R-II Inhibits Growth Arrest of A375 Cells by Human
but Not Cynomolgus IL-1
A375 cells were cultured for 3 days with purified recombinant human
IL-1 or with supernatant from COS cells transfected with human
or cynomolgus IL-1. Increasing amounts of shuIL1R-II were added
as inhibitor. Metabolic activity was measured by fluorescence 6 hr
after addition of Alamar Blue.
Both cynomolgus and rhesus macaque IL-1were used.
The two polypeptides are identical except for the pres-
ence of one additional amino acid (serine) at the C termi-
nus of the rhesus protein (Villinger et al., 1995; Totsuka
et al., 1998; D.E.S., unpublished data). Binding of shu-
IL1R-II to human IL-1s was included for comparison.
As has been previously demonstrated (McMahan et al.,
1991), shuIL1R-II binds to human IL-1 with a KA of
approximately 109 M–1 (Table 1). The dissociation rate
constant for this interaction is notably slow (kd  7 
10–5 s–1). The KA values of shuIL1R-II for human IL-1
and human IL-1ra are approximately two orders of mag-
nitude lower (Table 1). In contrast, and despite the bio-
logical effect observed in vivo in the rhesus monkeys,
the KA values of shuIL1R-II for cynomolgus IL-1 and
rhesus IL-1 were in the range of 1–3  106 M–1 (Table
1); indeed, this number is only an approximation, since
binding was too low to be measured accurately. The KA
of shuIL1R-II for cynomolgus IL-1ra was similar to thatFigure 1. Endotoxin-Induced Hemodynamic Changes in Rhesus
Monkeys Are Reduced by sIL1R-II for human IL-1ra, approximately 6  107 M–1 (Table 1).
Changes in (A) mean arterial pressure and (B) systemic vascular The lack of binding of shuIL1R-II to cynomolgus and
resistance after administration of endotoxin, in rhesus monkeys pre- rhesus IL-1s was confirmed in an alternative solid-
treated with shuIL1R-II or control protein, as indicated. Data are the phase binding assay (not shown) and in a biological
average of three (SVR) or five (MAP) control animals, and of two
assay. Treatment of the human melanoma cell line A375animals treated with sIL1R-II.
with human, rhesus, or cynomolgus IL-1 results in
growth arrest of the cells in a dose-dependent fashion.
Addition of increasing amounts of shuIL1R-II to theprotein, human serum albumin (Figure 1). In contrast,
injection of shuIL1R-II 2 hr before LPS administration assay inhibits the growth arrest induced by human IL-
1 but has no effect on arrest induced by cynomolgusblunted the drop in mean arterial pressure (to 83% of
baseline, compared to 65% of baseline in the control IL-1 (Figure 2) or rhesus IL-1 (not shown). The cyno-
molgus and rhesus IL-1 were active, as judged by theiranimals), and completely prevented the drop in systemic
vascular resistance (at 2 hr following LPS injection, SVR ability to inhibit proliferation of the A375 cells (Figure 2,
not shown) as well as their ability to bind human type Iremained at 98% of baseline in treated animals, com-
pared to 46% of baseline in control animals). Injection IL-1R measured using surface plasmon resonance (not
shown). Soluble huIL1R-II failed to bind recombinantof shuIL1R-II 30 min prior to LPS also ameliorated the
hemodynamic changes but was less effective (MAP, cynomolgus IL-1 or to inhibit it in a biological assay,
regardless of whether the IL-1was expressed in E. coli71% of baseline; SVR, 86% of baseline) than injection
2 hr prior to LPS. Thus, shuIL1R-II shows clear biological or in COS (monkey) cells. In addition, shuIL1R-II failed
to bind native cynomolgus IL-1 isolated from LPS-stim-activity in a nonhuman primate model of endotoxemia.
ulated peripheral blood monocytes.
To be certain that we were not being misled by cross-Binding of shuIL1R-II In Vitro to Monkey IL-1s
We attempted to characterize the binding of shuIL1R- species effects, we cloned and expressed the type II IL-1
receptors from both cynomolgus and rhesus monkeysII to monkey IL-1s using surface plasmon resonance.
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Table 1. Binding Measurements
human IL-1R type II
ka (1/Ms) kd (1/s) KA (1/M)
human IL-1 7.10  105 3.92  102 1.87  107
human IL-1 8.85  104 6.82  105 1.41  109
human IL-1ra 2.0  105 5.44  103 3.67  107
cyno IL-1 4.51  103 3.17  103 1.42  106
rhesus IL-1 9.36  103 3.66  103 2.56  106
cyno IL-1ra 2.34  105 3.68  103 6.34  107
cyno. IL-1R type II
ka (1/Ms) kd (1/s) KA (1/M)
cyno IL-1 2.75  104 9.34  103 2.95  106
rhesus IL-1 nd nd nd
human IL-1R type II & human AcP
ka (1/Ms) kd (1/s) KA (1/M)
human IL-1 7.62  105 3.38  104 2.28  109
human IL-1 9.50  104 6.78  107 1.79  1011
human IL-1ra 1.73  105 5.41  103 3.19  107
human IL-1R type II & cyno. AcP
ka (1/Ms) kd (1/s) KA (1/M)
cyno IL-1 4.11  104 2.33  104 2.00  108
rhesus IL-1 1.76  104 1.51  103 1.17  107
cyno IL-1ra 2.42  105 4.51  103 5.37  107
cyno. IL-1R type II & cyno. AcP
ka (1/Ms) kd (1/s) KA (1/M)
cyno IL-1 3.98  104 3.72  104 1.07  108
rhesus IL-1 3.16  104 1.39  103 2.28  107
Forward and reverse rate constants for binding of human and mon-
key cytokines to human and monkey sIL1R-II, in the presence or
absence of sAcP, were determined by Biacore as described in the
Figure 3. shuIL1R-II Is a Better Inhibitor in the Presence of sAcPExperimental Procedures. Affinity constants were calculated from
the rate constants. (A) COS7 cells transfected with an NFB-luciferase reporter plasmid
were incubated for 4 hr with varying concentrations of recombinant
rhesus IL-1 in the presence of soluble receptors. Cells were lysed
and luciferase activity measured to determine NFB activation.
(B) A375 cells were cultured for 3 days with increasing amounts of(D.E.S., unpublished data). The two have identical amino
purified recombinant IL-1 alone, or with the addition of 25 g/mlacid sequences. The recombinant monkey soluble IL1R-
of recombinant sIL1R-II, or with 25 g/ml recombinant sIL1R-II plusII bound to cynomolgus IL-1with a KA of approximately
20 g/ml recombinant sAcP. Cell viability was measured by fluores-3  106 M–1 (Table 1), comparable to the binding of
cence 6 hr after addition of Alamar Blue.
cynomolgus IL-1by human soluble IL1R-II. It also failed
to inhibit the biological activity of cynomolgus IL-1 in
the A375 assay (not shown). 36-fold, from KA  3  106 M–1 to KA  1.1  108 M–1
(Table 1). Moreover, although human sIL1R-II is capable
by itself of binding human IL-1 with good affinity (KA The Soluble Form of IL-1R AcP Enhances Binding of
shuIL1R-II In Vitro to Human and Monkey IL-1s 1.4  109 M-1), its affinity was also enhanced by soluble
AcP, by over 100-fold (to KA  1.8  1011 M–1) (Table 1).The cell-surface form of type II IL-1 receptor, in the
presence of ligand, is capable of interacting with sur- The enhancement in affinity was not restricted to IL-1;
in the presence of soluble AcP, the affinity of shuIL1R-face-bound IL-1 receptor accessory protein (Lang et al.,
1998; Malinowsky et al., 1998) and indeed the presence II for human IL-1 increased from KA  1.9  107 M–1 to
KA 2.3 109 M–1 (Table 1). In both cases, the increasedof AcP is required in order for high-affinity binding of
IL-1 to be seen with the mouse type II IL-1R (Malinow- affinity in the presence of AcP was due primarily to a
reduction in the dissociation rate constant. Consistentsky et al., 1998). In addition, the existence of a naturally
occurring, soluble version of AcP has been demon- with their physiological roles, there was no change in
the affinity of binding of shuIL1R-II to IL-1ra in the pres-strated (Greenfeder et al., 1995). We hypothesized that
the difference between the considerable beneficial ef- ence of AcP, leaving both available to inhibit the agonis-
tic action of IL-1 (Table 1).fect of shuIL1R-II in vivo (Figure 1), and the very modest
binding affinity in vitro (Table 1; Figure 2) might be due
to the presence of circulating, soluble AcP. The Soluble Form of IL-1R AcP Enhances
the Ability of shuIL1R-II to Inhibit HumanWe asked whether soluble AcP affected the affinity
of binding of IL-1s by type II IL-1 receptors using surface and Monkey IL-1s In Vitro
We wanted to confirm that the increased binding ofplasmon resonance. The presence of AcP enhanced the
binding of cynomolgus IL-1 to cynomolgus sIL1R-II by IL-1 by type II IL-1 receptors, conferred by soluble AcP,
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Figure 4. Serum Levels of AcP, sIL1R-II, and IL-1
The concentration, determined by ELISA, of proteins in serum from normal individuals is plotted. Left panel, soluble AcP; middle panel, soluble
IL1R-II; right panel, IL-1. Note that the minimum value in the right-hand panel is 0.125 pg/ml, the detection limit for the IL-1 ELISA. The IL-
1 values have not been corrected for the effect of sIL1R-II (see Experimental Procedures). The arrow indicates the median value in each
group.
translated into more effective inhibition. To this end, we pg/ml, with a median value of 0.43 pg/ml (Figure 4) and
a mean of 0.51 pg/ml (but see Experimental Procedures).assessed the ability of monkey and human sIL1R-IIs to
inhibit monkey IL-1 and human IL-1, respectively, in IL-1 levels were below the level of detection (3.9 pg/ml)
in all samples (not shown). In previous studies, naturallythe absence or presence of soluble AcP. As seen pre-
viously (Figure 2), shuIL1R-II by itself showed no inhibi- occurring plasma levels of soluble human type II IL-1R
were measured in 134 normal individuals by Jouvennetion of monkey IL-1 in a biological assay (Figure 3A).
AcP by itself also showed no inhibition. In the presence et al. (1998), who found a mean of 3.6  2.6 ng/ml
(range 	0.6– 10.5 ng/ml). Plasma levels of IL-1 wereof both shuIL1R-II and soluble AcP, however, a 25-fold
increase in IL-1 was required in order to achieve the determined in 21 normal individuals by Eastgate et al.
(1988), with a mean of 44.7 pg/ml. We do not know thesame biological response (Figure 3A). Soluble huIL1R-
II does have a modest inhibitory effect by itself on human reason for the large difference in IL-1 levels found in
our experiments versus those of Eastgate et al. Never-IL-1, but in the presence of soluble AcP, the inhibition
was also approximately 25-fold more effective (Figure theless, the normal circulating concentration of soluble
AcP is clearly much greater than that of either IL-13B). Therefore, soluble AcP confers on soluble IL1R-II
not only an increase in the affinity of binding but an (approximately 700,000-fold in our measurements) or
soluble IL1R-II (approximately 40-fold).increase in effectiveness as an inhibitor as well.
Soluble Levels of IL-1R AcP In Vivo Soluble Levels of IL-1R AcP during Inflammation
We sought to determine whether soluble AcP levelsThe ability of soluble AcP to enhance the inhibitory ca-
pacity of soluble IL1R-II is only biologically relevant if would differ between normal individuals and those with
inflammatory disease. We measured sAcP in serum fromthe level of soluble AcP in vivo is sufficient. We therefore
wanted to measure the normal circulating level of solu- 32 patients suffering from rheumatoid arthritis (not
shown). The median value from the arthritis patientsble AcP. An ELISA was developed for this purpose and
used to determine sAcP concentrations in the serum of was 312 ng/ml (range 103 to 1215.4 ng/ml). The main
difference between the arthritis patients and the normals100 normal individuals. The median soluble AcP concen-
tration in this panel was 311.5 ng/ml (mean 329 ng/ml), is the existence of a small number of patients with higher
levels of circulating soluble AcP (22% of arthritis pa-with a range of 91.6–600.3 ng/ml (Figure 4). Virtually all
samples (98%) are within 2-fold of the mean. tients have levels greater than 2 the median value).
We also explored the variation in soluble AcP levelsFor comparison, we also measured levels of endoge-
nous sIL1R-II, IL-1, and IL-1 in this same panel of in animal models of disease. We examined mouse mod-
els of arthritis (in DBA/1 mice) and inflammatory bowelserum samples. sIL1R-II levels ranged from 2.8 to 16.2
ng/ml, with a median value of 7.6 ng/ml (Figure 4) and disease (in Balb/c mice). In both strains, soluble AcP
levels were approximately 4 g/ml, and declined slightlya mean of 7.9 ng/ml. IL-1 levels were below the level
of detection (0.125 pg/ml) in 28 of the samples; in the during the course of the inflammation (data not shown).
The same general trend was seen during endotoxemiaother 72 samples, they ranged from 0.126 pg/ml to 1.213
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in monkeys, although the initial soluble AcP level was
approximately 1.1 g/ml (data not shown). Thus, circu-
lating soluble AcP levels are even higher in monkey and
mouse than they are in human, and in all three species,
do not appear to change significantly during inflam-
mation.
Alternatively Spliced mRNA Encoding Soluble AcP
It has been known for some time that the IL-1 receptor
accessory protein gene is transcribed into two splice
forms of mRNA (Greenfeder et al., 1995; Jensen et al.,
2000). One of these encodes the signaling, transmem-
brane form of AcP, while the other encodes the soluble
form. The latter mRNA has been characterized only in
liver cells, where it is regulated modestly (Jensen et al.,
2000).
To gain information about the source of circulating
soluble AcP, we surveyed a wide variety of cell types
by quantitative PCR for their expression of both mRNA
isoforms. As can be seen in Figure 5, many tissues ex-
press the mRNA isoform encoding soluble AcP. The
highest levels in our survey were found in adult liver,
skin, and placenta, and in certain fetal organs. Generally,
soluble AcP mRNA was present at approximately 5%
to 10% the level of mRNA encoding full-length AcP.
Notable exceptions are the T84 intestinal cell line and
activated HepG2 cells, in which there is a slight excess
of mRNA encoding soluble AcP (data not shown). In
general, the amount of mRNA encoding soluble AcP
does not change much with cell stimulation (not shown).
Among the settings in which soluble AcP does show
regulation are in human peripheral blood mononuclear
cells, in which there is a 1.5- to 4-fold increase upon
stimulation with PMA/ionomycin, tetanus toxoid, or
PHA, and in human peripheral blood B cells, which show
a 10-fold decrease in mRNA when treated with a combi-
nation of the Cowan strain of Staphylococcus aureus,
Figure 5. Expression of mRNA Encoding Different Forms of AcPCD40 ligand, and IL-4. We specifically examined the
Taqman quantitative PCR was performed on a panel of RNAs fromresponse of peripheral blood monocytes to anti-inflam-
normal human tissue, using primers specific for the soluble (topmatory agents, including IL-4, IL-13, the combination of
panel) and full-length (middle panel) forms of AcP mRNA. ExpressionIL-4 and IL-13, and dexamethasone, since these treat-
levels are plotted as the ratio of the threshold detection value (CT)
ments have been shown to induce expression of the of the AcP mRNA to that of a control gene (hypoxanthine-guanine
type II IL-1 receptor on monocytes and neutrophils phosphoribosyl transferase). The bottom panel shows the ratio of
(Mantovani et al. 2001). Although each of these treat- soluble to full-length mRNA.
ments strongly induced IL1R-II mRNA, none of them
led to a significant change in the level of the mRNAs
encoding either full-length or soluble AcP, at either 4, L selectin (CD62L). Neither of these agents induced the
shedding of AcP. Other cell lines and conditions examined7, or 24 hr after stimulation (data not shown).
For many proteins that have both transmembrane and in which we failed to see shedding of AcP using FACS
include primary human monocytes, the human B cell linesoluble forms, the soluble form is generated by proteo-
lytic cleavage of the membrane-bound precursor (shed- Namalwa, and the monkey CV-1/EBNA cell line (McMa-
han et al., 1991) transfected with human type II IL-1ding), rather than being encoded by a separate mRNA.
We asked whether shedding might also contribute to receptor or human AcP, all treated with (or without) PMA.
We explored further the possibility that some sAcPthe circulating pool of soluble AcP. We stained cells
with antibodies against AcP and against a control pro- might be generated proteolytically by use of the metallo-
proteinase inhibitor TAPI (Mohler et al., 1994) withtein known to be shed, before and after treatment with
a known shedding stimulus, and compared their profiles HepG2 cells. This inhibitor and others like it have been
demonstrated to inhibit the shedding of a number ofby FACS analysis. Figure 6 demonstrates that, as ex-
pected, there was considerable shedding of type II IL-1 cell-surface molecules including pro-TNF, IL-2R, and
IL-1R type II (Mullberg et al., 1997; Orlando et al., 1997).receptor from HepG2 cells after treatment with PMA.
There was no reduction, however, in the amount of sur- Spontaneously produced soluble AcP accumulated in
the supernatant of the cells to 9.2 ng/ml after 48 hr, andface AcP under the same conditions. Similarly, human
neutrophils were induced by either PMA or LPS to shed to 12.3 ng/ml after 72 hr. Addition of 50 M TAPI had
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Figure 6. Lack of Shedding of AcP
HepG2 cells express both AcP and type II IL-1R, as demonstrated by FACS analysis (A: light line, isotype control; shaded peak, IL1R-II; heavy
line, AcP). Following treatment with PMA, there is a loss of type II IL-1R (B: shaded peak, before; open peak, after) from the cell surface, but
no loss of AcP (C). Similarly, primary human neutrophils express cell-surface L-selectin and AcP (D: light line, isotype control; shaded peak,
L-selectin; heavy line, AcP). Stimulation with either PMA or LPS leads to loss of L-selectin (E: dark shading, no treatment; light shading, LPS;
light line, PMA) but not AcP (F).
no effect on the accumulation (9.9 ng/ml and 13.6 ng/ work to be published separately (Smith et al., 2002), we
have mapped the difference in behavior of human andml, respectively, after 48 and 72 hr). Western blot analy-
monkey IL-1 to a single amino acid change. Regard-sis (not shown) confirmed the lack of effect of TAPI on
less, the soluble AcP effect likely explains the ability ofsAcP accumulation in the medium. Control experiments
sIL1R-II to reduce the effects of endotoxemia in mon-demonstrated that TAPI was capable of inhibiting com-
keys (Figure 1), despite the poor binding of human (orpletely the PMA-induced shedding of type II IL-1R from
monkey) sIL1R-II alone to monkey IL-1 in vitro (Tablethe HepG2 cells. Thus, in this limited set of cell types
1; Figure 2).examined, we have found no evidence to support the
Yet another surprising finding was the high serum levelidea that some of the circulating sAcP is generated by
of soluble AcP (approximately 300 ng/ml in humans, 1shedding of the transmembrane form.
g/ml in monkeys, and higher still in mice). These values
can be contrasted to the levels of soluble IL1R-II (ap-
Discussion proximately 7 ng/ml) and IL-1 (approximately 0.4 pg/
ml) found in human serum (Figure 4). It is not obvious why
The experiments presented in this paper reveal a pre- such high levels of sAcP are desirable. One possibility
viously unappreciated interaction between the soluble would be to ensure that the binding of IL-1 or IL-1 by
forms of IL1R-II and AcP. Although logically this interac- sIL1R-II is driven to completion. Another alternative (not
tion might have been predicted, given the ability of the mutually exclusive) is that sAcP interacts with serum
cell-surface forms of these proteins to associate, the components other than ligand-bound IL1R-II. The high
magnitude of the increase in affinity for the agonist IL- degree of sequence conservation of AcP between hu-
1s (30- to 100-fold) was not expected, nor was the con- man and mouse (85% amino acid identity in the extracel-
version of sIL1R-II from a poor inhibitor of IL-1 to a lular region, compared to 62% amino acid identity be-
reasonably effective inhibitor in the presence of excess tween the extracellular regions of human and mouse
sAcP. The improvement in affinity is almost entirely due type II IL-1R and 64% amino acid identity between the
to a decrease in the dissociation rate constant. Notably, extracellular regions of human and mouse type I IL-1R)
the presence of soluble AcP does not increase the affin- would be consistent with a need for AcP to interact with
ity of sIL1R-II for IL-1ra, thus maintaining the ability of several different proteins.
both antagonists to regulate IL-1 action. There is little difference in the distribution of serum
Also unexpected was the inability of monkey IL-1 to soluble AcP levels between normal individuals and rheu-
bind to either human or monkey sIL1R-II in the absence matoid arthritis patients. In contrast, soluble AcP levels
of sAcP. We have not yet demonstrated that this is also drop by about half over the course of several acute
true for the surface forms of the receptor proteins in inflammatory models (monkey endotoxemia, mouse col-
monkey. Nevertheless, this finding raises the question lagen-induced arthritis, and mouse colitis). The reason
of why the regulation of IL-1 activity should be different, for the decrease is unknown, as is the biological implica-
tion. In our preliminary explorations, we have found iso-at least in detail, between humans and macaques. In
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by affinity chromatography using recombinant human sIL1R-I cova-lated examples in which mRNA levels encoding soluble
lently attached to Affigel-10 resin. Concentrations were determinedAcP are regulated by cell stimuli. However, we have not
by amino acid analysis.found evidence for the kind of dramatic and substantial
Accessory Proteins
changes in expression level seen with IL-1ra or type II Cynomolgus IL-1 receptor accessory protein cDNA was cloned from
IL-1 receptor. We have also shown that shedding of the the same RNA source used to clone cynomolgus IL-1ra. Rhesus
IL-1 receptor accessory protein cDNA was cloned following PCRcell-surface form does not appear to be a major means
amplification of mRNA derived from tonsil. PCR primers were de-of generating soluble AcP.
signed from the 5
 and 3
 untranslated regions of human AcP. TheWhen the soluble form of AcP was first discovered,
protein sequences of cynomolgus and rhesus AcP proteins wereit was attractive to hypothesize that this molecule could
identical to each other, and 99% identical to human AcP. Biacore
associate with ligand-bound cell-surface type I IL-1 re- measurements utilized Ig fusions (Baum et al., 1994) of human and
ceptor, displacing full-length AcP and thereby contribut- cynomolgus sAcP that were purified by chromatography on protein
A sepharose. Soluble human sAcP tagged at its C terminus with aing to the control of IL-1 responses. Jensen et al. (2000),
peptide containing the FLAG epitope followed by six histidine resi-however, were unable to demonstrate such an associa-
dues (…RSGSSDYKDDDDKGSSHHHHHH*), expressed in COS cellstion. Whether soluble AcP might associate with the li-
and purified by immobilized metal affinity chromatography, wasgand-bound form of cell-surface type II IL-1 receptor to
used in A375 assays. The human ELISA standard was untagged and
enhance the affinity of IL-1 binding is unknown. The was purified by conventional chromatography. COS cell expression
ligand-bound form of cell-surface type II IL-1 receptor supernatants were exposed in batch to Heparin Sepharose 6 Fast
Flow (Pharmacia), previously equilibrated in 50 mM Tris-HCl, 7.5)is able to bind and sequester full-length AcP in a nonpro-
at a resin:supernatant ratio of 1:12, overnight at 4C. Under theseductive complex (Lang et al., 1998; Malinowsky et al.,
conditions AcP does not bind to the Heparin resin. Unbound material1998). One might imagine that ligand-bound soluble type
was then batch exposed to a wheat germ agglutinin (WGA) resinII IL-1R could also tie up full-length AcP. However, the
(Vector), previously equilibrated in 50 mM Tris-HCl (pH 7.5) con-
data in Figure 2 suggest that this is not the case; if it taining 50 mM N-acetylglucosamine (binding buffer), at a resin:su-
were, then sIL1R-II should also be able to inhibit cyno- pernatant ratio of 1:25, overnight at 4C. Following overnight binding
the WGA resin was collected in a column, washed with 10 columnmolgus IL-1 (Figure 2; Table 1).
volumes of binding buffer, and the sAcP eluted with a linear gradientThe findings reported here enhance our understand-
of 50 mM-1.0 M N-acetylglucosamine in 50 mM Tris-HCl (pH 7.5).ing of the complexity of IL-1 regulation. Whether the
Fractions containing sAcP were pooled and concentrated and thenlarge amount of circulating soluble AcP contributes to
applied onto a Superdex 75 HiLoad 26/60 column (Pharmacia) pre-
the regulation of additional cytokines remains an open viously equilibrated with PBS at a flow rate of 2 ml/min. Soluble
question. AcP behaved as a monomer, displaying a retention time consistent
with a molecular weight of60 kDa. Fractions were analyzed by SDS
PAGE. Pure fractions were pooled and concentration determined
Experimental Procedures by amino acid analysis. To generate standards for the nonhuman
ELISAs, soluble AcP proteins from cynomolgus and mouse were
Protein Reagents tagged at their C termini with a sequence encoding the FLAG epitope
Multiple forms of all proteins were used. The cloning of IL-1 and followed by six histidine residues (…RSGSSDYKDDDDKGSSHHHH
type II IL-1 receptor from rhesus and cynomolgus monkeys is de- HH*) and purified by immobilized metal affinity chromatography.
scribed elsewhere (Smith et al., 2002). Descriptions of the other Specific AcP amino acid residues included in the various constructs
proteins are as follows. are as follows: human AcP, residues 1-354 of Genbank AF029213;
Type II IL-1 Receptors cynomolgus AcP, residues 1-359 of Genbank AY182233; mouse
Biacore measurements utilized Ig fusions (Baum et al., 1994) of AcP, residues 1-359 of Genbank X85999.
human, rhesus, and cynomolgus soluble IL1R-II that were expressed
by transient transfection of COS cells and purified by chromatogra- Endotoxemia in Monkeys
phy on protein A sepharose. The primate endotoxemia experiments, Domestic born, male rhesus monkeys, Macaca mulatta, mean
as well as biological assays with the A375 cell line, utilized untagged weight 4.5  0.5 kg, from the Veterinary Resource Facility at the
soluble human IL1R-II made by stable expression in CHO cells and University of Maryland, Greenebaum Cancer Center, were used in
purified by affinity chromatography using human IL-1 covalently these studies. Animals were anesthetized with ketamine (10 mg/kg,
attached to Affigel-10. Concentration was determined by amino acid im) and immobilized in a well-padded, specifically designed restraint
analysis. Specific amino acid residues included in the soluble con- system to allow placement of arterial and venous catheters. Follow-
structs are as follows: human IL1R-II, residues 1-346 of Genbank ing line placement, the animals were allowed to awaken, and base-
NM_004633; cynomolgus IL1R-II, residues 1-346 of Genbank line hemodynamic measurements taken. Animals received an infu-
AY172102; rhesus IL1R-II, residues 1-346 of Genbank AY172100. sion over 10 min of E. coli endotoxin (0111:B4), 6 mg/kg bw, mixed
Cynomolgus and rhesus type II IL-1 receptors are identical. in 20 ml of normal saline. At 30 min and every hour up to 5 hr
IL-1 Ligands after endotoxin, hemodynamic measurements were obtained on the
Human IL-1, IL-1, and IL-1ra used in Biacore experiments were restrained and resting but unanesthetized animals. Once measure-
generated at Amgen and purified by conventional means. Human ments were completed, animals were anesthetized with ketamine,
ligands used in the A375 assays were purchased from R&D Systems venous and arterial lines removed, and the animals returned to their
(Minneapolis, MN). Cynomolgus IL-1ra cDNA was cloned following cages under observation by technical staff until they were awake,
PCR amplification of mRNA derived from peripheral blood lympho- alert, and responsive. Experimental animals received a subcutane-
cytes (kindly provided by SNBL, Everett, WA) that had been cultured ous injection of soluble IL-1 receptor type II (sIL1R-II) at 200 g/kg
for 3.5 hr in LPS and human CD40 ligand (both at 1 g/ml). PCR either 2 hr or 30 min prior to endotoxin. In addition, the animals
primers were designed from the 5
 and 3
 untranslated regions of were infused with sIL-1RII (200 g/kg/hr, mixed in normal saline)
human IL-1ra. The cynomolgus and human IL-1ra amino acid se- via continuous iv drip starting 5 min prior to LPS infusion and contin-
quences are 96% identical. The cloning of cynomolgus and rhesus uing over the next 4 hr. Control animals were treated identically
IL-1 ligands is described elsewhere (Smith et al., 2002). PCR prim- except that they received human serum albumin (Cappel, catalog
ers were designed based on Genbank accession numbers D63353 #55912) instead of sIL1R-II.
(cynomolgus; the sequence we subsequently derived differs from
the Genbank version at one amino acid) and U19845 (rhesus). Full- Cynomolgus Peripheral Blood Monocytes
length cynomolgus IL-1ra, and the mature forms of cynomolgus and Cynomolgus primary cells were isolated from whole blood (kindly
provided by Shin Nippon Biomedical Laboratories in Everett, Wash-rhesus IL-1, were expressed by transient transfection and purified
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ington). PBMCs were isolated from heparinized blood by density PBS (pH 7.2) with 0.05% Tween-20 (PBST) prior to use. Samples
and reagents were dispensed into the wells in the following se-centrifugation. The cells were cultured in RPMI1640 with 10% FBS
for 2 hr at 37C at a density of 5  106 /ml. Nonadhering cells were quence, each separated by an incubation period and wash step:
(1) serum samples and CHO-derived human sAcP concentrationwashed away and the remaining cells cultured for 2 hr in the pres-
ence of 1 g/ml LPS and 35S Cys  Met to metabolically label newly standards diluted in a sample buffer composed of PBST with 0.01%
casein and 0.5 mg/mL purified rat IgG; (2) biotinylated anti-huAcPtranslated proteins. ATP was then added to the culture to 6 mM
and the cells incubated an additional 2.5 hr. Exported native IL-1 mouse IgG1 monoclonal antibody Clone 60 (Amgen Corporation)
diluted in PBST; and (3) peroxidase-labeled streptavidin (Jacksonwas collected in the conditioned medium and used for direct binding
studies with recombinant IL-1 receptors. ImmunoResearch Laboratories, West Grove, PA) diluted in PBST.
Color was developed with TMB peroxidase substrate (Kirkegaard &
Perry Laboratories, Gaithersburg, MD). The reaction was quenchedAffinity Measurements
with acid and optical densities (ODs) were determined at a wave-Affinities were determined by surface plasmon resonance, using a
length of 450 nm. The dose-response curve, constructed of concen-Biacore 3000 instrument at 25C with research-grade CM5 sensor
tration standards in the range of 4-256 ng/mL, was fitted to a four-chips. A capture system was employed with goat anti-human IgG
parameter logistic model. Sample concentrations were interpolatedFc-specific antibody (Jackson ImmunoResearch Laboratories, West
from the fitted curve and corrected for dilution factor. Control experi-Grove, PA) immobilized using standard amine-coupling chemistry.
ments examined the ability of the assay to detect both free sAcPImmobilized capture antibody alone was used as a reference sur-
and sAcP complexed with sIL1R-II and IL-1. The addition of up toface. sIL1R-II.Fc at 7.5 g/ml in HBS-EP (10 mM HEPES, 150 mM
a 100-fold molar excess of both sIL1R-II and IL-1 did not affectNaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20 [pH 7.4] from Biacore
the measured soluble sAcP levels (not shown).AB) with 0.1 mg/ml BSA or a mixture of sIL1R-II.Fc and sAcP.Fc
Cynomolgus Macaque AcP ELISA(7.5 g/ml each, in the same buffer) was injected over the captured
sAcP levels in cynomolgus sera were determined by a modifiedantibody surface at 10 l/min for 3 min to obtain a density of 300-
version of the human sAcP ELISA described above. The two meth-600 resonance units. Recombinant IL-1, IL-1, or IL-1ra in HBS-
ods were identical except that purified rat IgG was omitted fromEP with 0.1 mg/ml BSA was injected over both the receptor and
the sample buffer and concentration standards were prepared fromreference surfaces at concentrations ranging from 1000 nM down
cynomolgus sAcP.FlagHis in the range of 2–128 ng/mL. Pilot experi-to 1 nM at a flow rate of 50 l/min. The complex was allowed to
ments showed that the ELISA values obtained with an untagged,associate for 2 to 3 min and dissociate for 3 to 7 min. If necessary,
conventionally purified sAcP standard were identical to those ob-both surfaces were regenerated with a single injection of 10 mM
tained with sAcP.FlagHis. Control experiments indicated that theglycine HCl (pH 1.5) for 30 s at a flow rate of 50 l/min. Duplicate
presence of sIL1R-II and IL-1  reduced the measured sAcP values,injections of each sample and triplicate injections of a buffer blank
as follows: at a 1:1:1 ratio of sAcP:sIL1R-II:IL-1, the measured AcPwere injected in random order. The data were fit globally to a simple
value was 87% of control (obtained in the absence of sIL1R-II and1:1 interaction model with local Rmax using BIAEvaluation 3.1
IL-1 ); at a 1:10:10 ratio, the value was 62% of control; at a 1:100:100Software.
ratio, the value was 8% of control. Ratios of 1:10:1 and 1:1:10 eachA375 Assay
gave 100% of the control value for sAcP. Since sAcP levels areA375.S2 cells (ATCC catalog number CRL 1972) at 1  104 cells
typically orders of magnitude higher than sIL1R-II or IL-1  levels,per well in 96-well flat-bottom tissue culture-treated plates (Costar
interference was thought not to be an issue.#3596) were incubated with the specific cytokines and soluble re-
Murine AcP ELISAceptors indicated in the figures in a total volume of 100 l of DMEM
Murine serum sAcP concentrations were also determined by ELISA.containing 5% fetal bovine serum. After 72 hr at 37C, 10% CO2,
Wells of Nunc Maxisorp microtiter plates were coated with a solutionplate wells were washed once with PBS and a solution of Alamar
of anti-muAcP rat IgG1 monoclonal antibody M215 (Amgen Corpora-Blue fluorescent metabolic indicator dye (BioSource Int., Camarillo
tion, Seattle, WA) and incubated overnight at 2–8C. The coatedCA) was added to all wells and incubated for another 4–6 hr. Fluores-
wells were washed with PBST prior to use. Samples and reagentscence was determined using a TECAN SPECTRAFluor plate reader
were dispensed into the wells in the following order, each separatedat 560 nm excitation wavelength and 595 nm emission wavelength.
by an incubation period and wash step: (1) serum samples andThe mean values from at least two replicate wells are plotted. In
murine sAcP.FlagHis concentration standards diluted in PBST withFigure 2, the purified recombinant human IL-1 standard was used
0.1% BSA (PBSAT); (2) rabbit anti-muAcP antiserum (Amgen Corpo-at 3 ng/ml, and supernatant from COS cells expressing either human
ration, Seattle, WA) diluted in PBSAT; and (3) peroxidase-labeledor cynomolgus IL-1was used at a final dilution of 1:2500. Metabolic
goat anti-rabbit IgG (Jackson Immunoresearch Laboratories, Westlabeling experiments suggested that comparable amounts of human
Grove, PA) diluted in PBSAT. Color was developed with TMB peroxi-and monkey IL-1 were present in the COS cell-conditioned media.
dase substrate. The reaction was quenched with acid and optical
densities (ODs) were determined at a wavelength of 450 nm. TheCOS Cell Assay
dose-response curve, constructed of concentration standards inCOS7 cells in DMEM plus 5% fetal bovine serum were transfected
the range of 0.125-8 ng/mL, was fitted to a four-parameter logisticusing Fugene 6 reagent (Roche Molecular Systems, Pleasanton CA)
model. Sample concentrations were interpolated from the fittedin 24-well plates with 200 ng of an NFB luciferase plasmid. Twenty
curve and corrected for dilution factor. Pilot experiments showedhours later, soluble receptors were added to cells in a final volume
that the sAcP ELISA values obtained with an untagged, affinity-of 0.4 ml (final concentrations: 25 g/ml of human sIL1R-II and 20
purified sAcP standard were approximately double those obtained
g/ml of cynomolgus sAcP-FlagHis). Affinity-purified recombinant
with the sAcP.FlagHis standard. In control experiments, the mea-rhesus IL-1 was added and the assay was allowed to proceed for
sured values for sAcP were unaffected by a 100-fold excess of4 hr. Cells were washed three times with PBS and then lysed with
sIL1R-II and IL-1  (not shown).150 l Passive Lysis Buffer (Promega). The luciferase activity in 8
l of lysate was measured using a Lumat LB 9507 luminometer
(EG&G Berthold). All samples were assayed in quadruplicate and Other ELISAs
average RLU values were plotted. Soluble IL1R-II
Wells of 96-well microtiter plates (“Maxisorp,” Nunc, Roskilde, Den-
mark) were coated with anti-shuIL-1R-II monoclonal antibody M25Measurements of Soluble AcP Levels in Serum
Human AcP ELISA (Amgen Corporation, Seattle, WA) and incubated overnight at 2-8C.
The coated wells were washed with PBS (pH 7.2) with 0.05% Tween-AcP concentrations were estimated by an ELISA employing AcP-
specific monoclonal antibodies to capture and detect soluble AcP 20 (PBST) prior to use. Samples and reagents were dispensed into
the wells in the following sequence, each separated by an incubationin serum. Wells of 96-well microtiter plates (“Maxisorp,” Nunc,
Roskilde, Denmark) were coated with anti-huAcP mouse IgG1 period and wash step: (1) serum samples and CHO-derived shuIL-
1R-II concentration standards diluted in a sample buffer composedmonoclonal antibody M355 (Amgen Corporation, Seattle, WA) and
incubated overnight at 2–8C. The coated wells were washed with of PBST with 0.01% casein, 5 mM EDTA, and 5% normal rat serum;
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and (2) peroxidase-labeled anti-shuIL-1R-II monoclonal antibody treated with 100 ng/ml PMA (Sigma, St. Louis, MO) or LPS (Esche-
richia coli 005:B5; Difco, Detroit, MI) for 40 min. After washing andM4 (Amgen Corporation) diluted in PBST with 0.01% casein and 5
mM EDTA. Color was developed with TMB peroxidase substrate blockade of nonspecific binding using 200 g/ml normal goat IgG
(Sigma), they were stained with 5 g/ml mouse IgG1 monoclonal(Kirkegaard & Perry Laboratories, Gaithersburg, MD). The reaction
was quenched with acid and optical densities (ODs) were deter- antibodies directed against human AcP (M355, Amgen), type II IL-1
receptor (M2, Amgen), or L selectin (CD62L, R&D Systems, Minneap-mined at a wavelength of 450 nm. The dose-response curve, con-
structed of concentration standards in the range of 78.1-5000 pg/ olis, MN), or with control mouse IgG1 (MOPC-21 protein, Phar-
mingen, San Diego, CA), then with PE-conjugated goat anti-mousemL, was fitted to a four-parameter logistic model. Sample concen-
trations were interpolated from the fitted curve and corrected for antiserum (Sigma), and analyzed by flow cytometry. For the TAPI
experiments, 3  106 HepG2 cells were seeded in 10 ml of mediumdilution factor. The presence of IL-1 and/or soluble AcP did not
interfere with the assay. in 10 cm dishes, with or without 50 M TAPI (Amgen Corporation).
Medium was collected at 48 and 72 hr and assayed by ELISA forIL-1
IL-1 concentrations were measured using the Quantikine human the presence of soluble human AcP. As a control, PMA (100 ng/ml)
was added to some cells 24 hr after seeding, with or without 50 MIL-1  Immunoassay (Catalog #DLA50), manufactured by R&D Sys-
tems (Minneapolis, MN). The manufacturer states that soluble IL-1 TAPI, and the cells analyzed by FACS to confirm that shedding of
type II IL-1R was completely inhibited by TAPI (not shown).receptors do not interfere with the assay unless present at greater
than 10 ng/ml (sIL1R-I) or greater than 30 ng/ml (sIL1R-II).
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